February 2019

Poltreg presented its current strategy at LSX World Congress in London. The Congress is a high-calibre, senior executive, conference, exhibition and partnering event providing the education, strategies, solutions and contacts that life science executives need to enable more effective investment, planning and strategic growth within their businesses.

More: https://www.lsxleaders.com/lsx-world-congress/showcases/poltreg

September 2018

Prof. Piotr Trzonkowski gave a lecture on TREG method during European Congress of Immunology in Amsterdam. The congress is the biggest and the most important European event on immunology taking place every three years in different European cities.

More: https://www.eci2018.org/program/track-c/

June 2018

PolTREG has been awarded 2 500 000 Euro grant in Horizon2020 in the healthcare biotechnology sector.(project 830559 – TREG: TREG – innovative cell therapy targeting Diabetes Type 1).  We are the only Polish SME company that received support in this instrument in the area of healthcare. The money will be spent on the preparations to phase III clinical trial in type 1 diabetes.

More: https://www.kpk.gov.pl/?p=44366


April 2018

Report on adverse effects from clinical trials on type 1 diabetes and multiple sclerosis confirmed good safety profile of the treatment.

More: http://strategmed.tregs.gumed.edu.pl/

February 2018

Scientists from Poltreg are co-authors of the minimum information model on Treg cell therapy (MiTREG). The paper describing MiTREG brought together over 50 scientists from all over the world.

More: https://www.frontiersin.org/articles/10.3389/fimmu.2017.01844/full

January 2018

Last patient recruited into phase I trial on multiple sclerosis in STRATEGMED TREGS programme. Full results of the study will be available in second quarter of 2019.

More: http://strategmed.tregs.gumed.edu.pl/

December 2017

Inventor of TREG method Prof. Piotr Trzonkowski has received the Foundation for Polish Science Prize 2017 in the life and earth sciences for studies on regulatory T cells and their pioneering use in cell therapy of human diseases. This is the most important scientific prize in Poland.

More: https://www.fnp.org.pl/en/prof-piotr-trzonkowski-laureat-nagrody-fnp-2017/



September 2017

Last patient recruited into phase II trial on type 1 diabetes in STRATEGMED TREGS programme. Full results of the study will be available in third quarter of 2019.

More: http://strategmed.tregs.gumed.edu.pl/

June 2017

Scientists from Poltreg took a part in the final meeting of the “Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies (AFACTT). This is Europe’s Biggest Research Network on cell-based tolerance-inducing therapies that brings together around 100 scientists from 20 European universities.

More: https://www.afactt.eu/

Mai 2017

Scientists from Poltreg published report with new data on laboratory technique increasing stability and quality of TREG preparation used in the treatment. The method is a subject of new patent application.

More: https://www.nature.com/articles/s41598-017-10151-1

December 2016

Scientists from Poltreg published report describing long-term effects of the therapy. The report proves that the patients treated with TREG cells could produce insulin more than 2 years after administration of the preparation.

More: https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-016-1090-7